Brokerage firm Motilal Oswal initiated coverage on , Jefferies has a buy rating on and Morgan Stanley recommended an overweight stance on and . Motilal Oswal initiated coverage on Mankind Pharma with a buy rating and a target of Rs 2,650. The company is working on multiple levers to boost growth over the next three to five years.
The company is increasing the scope of business in chronic therapies. It is enhancing its presence in metro/Tier-l cities. The brokerage firm expects a 16% earnings CAGR for Mankind over FY24-27.
Jefferies maintained a buy rating on NYKAA with a target price of Rs 220. The beauty and personal care segment (BPC) offers significant growth headroom. An increase in user awareness should drive category growth.
Fashion plays in a niche (premium) market. The global investment bank sees a clear need among customers who are value-conscious and not just discount-seeking. BPC margins should be range-bound in the short term as growth is a priority.
Morgan Stanley maintained an overweight rating on Tata Consumer with a target price of Rs 1288. The management is focused on growing the business and improving margins and return ratios for the existing business. The core tea and salt business will target 5% volume growth and 7-8% value growth over the medium term.
The company will continue to evaluate inorganic opportunities. Nourishco, Sampann, Soulful, Capital Foods, and Organic India will grow at 30%. EBITDA margins are expected to improve by 75-125bps annually.
M.
